GH | tickerfilter.com

Fundamental analysis

49%

Profitability 43%

Dept financing 43%

Liquidity 73%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.12%

1 Month

-13.42%

3 Months

-12.45%

6 Months

51.58%

1 Year

131.94%

2 Year

111.16%

Key data

Stock price

$91.20

P/E Ratio

0.00

DAY RANGE

$89.00 - $93.00

EPS

-$3.32

52 WEEK RANGE

$34.88 - $120.74

52 WEEK CHANGE

$154.46

MARKET CAP

12.874 B

YIELD

N/A

SHARES OUTSTANDING

131.170 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-06-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$1,654,554

AVERAGE 30 VOLUME

$2,071,872

Company detail

CEO: Helmy Eltoukhy
Region: US
Website: guardanthealth.com
Employees: 1,790
IPO year: 2018

Issue type:
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.

GH - Guardant Health, Inc.